March 4, 2026 · Form 4 insider transaction
Reardon Andrew sold 300 shares of Ligand Pharmaceuticals Incorporated at $201.70 per share, a transaction worth $60.5K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.